Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Albendazole - GSK

Drug Profile

Albendazole - GSK

Alternative Names: Albenza; Bilutac®; Escazole®; Eskazole®; Proftril®; SKF 62979; Zentel®

Latest Information Update: 02 Jul 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GlaxoSmithKline
  • Developer GSK; PharmAust
  • Class Anthelmintics; Benzimidazoles; Carbamates; Small molecules
  • Mechanism of Action Tubulin inhibitors; Vascular endothelial growth factors inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Helminthiasis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Helminthiasis
  • Discontinued Ascites

Most Recent Events

  • 03 Feb 2021 Discontinued - Phase-I for Helminthiasis (In volunteers) in China (PO) (GlaxoSmithKline pipeline, February 2021)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Helminthiasis(In volunteers) in China (PO, Tablet)
  • 31 May 2013 Phase-I/II clinical trials in Ascites in Australia (PO)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top